Clinical Trial Update: Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer [Phase 1]

View source ↗

Summary

Phase I study investigating the combination of Actinium-225 labeled J591 antibody and Lutetium-177 PSMA small molecule in progressive metastatic castration-resi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• 177Lu-PSMA small molecule (Lutetium-177 labeled PSMA-targeted small molecule)
• 225Ac-J591 (Actinium-225-labeled J591)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Prostate Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING